The fucoidan from the brown seaweed Ascophyllum nodosum ameliorates atherosclerosis in apolipoprotein E-deficient mice.
Animals
Apolipoproteins E
/ deficiency
Ascophyllum
/ chemistry
Atherosclerosis
/ drug therapy
Humans
Hyperlipidemias
/ complications
Liver X Receptors
/ genetics
Male
Membrane Transport Proteins
/ genetics
Mice
Mice, Inbred C57BL
Mice, Knockout
Plant Extracts
/ administration & dosage
Polysaccharides
/ administration & dosage
Receptors, LDL
/ genetics
Seaweed
/ chemistry
Sterol Regulatory Element Binding Protein 1
/ genetics
Journal
Food & function
ISSN: 2042-650X
Titre abrégé: Food Funct
Pays: England
ID NLM: 101549033
Informations de publication
Date de publication:
01 Aug 2019
01 Aug 2019
Historique:
pubmed:
1
8
2019
medline:
6
2
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
Hyperlipidemia is a major cause of atherosclerosis. Reverse cholesterol transport (RCT) is believed to attenuate hyperlipidemia and the progression of atherosclerosis. Although fucoidans are reported to have hypolipidemic effects, the underlying mechanisms are unclear. Furthermore, few reports have revealed the anti-atherosclerotic effects and the underlying mechanisms of fucoidans. This study was designed to investigate the anti-atherosclerotic effect and mechanisms of the fucoidan from seaweed A. nodosum. Our results demonstrated that the fucoidan administration ameliorated atherosclerotic lesion and lipid profiles in a dose-dependent manner in the apolipoprotein E-deficient (apoE
Substances chimiques
Apolipoproteins E
0
Liver X Receptors
0
Membrane Transport Proteins
0
Npc1l1 protein, mouse
0
Plant Extracts
0
Polysaccharides
0
Receptors, LDL
0
Sterol Regulatory Element Binding Protein 1
0
fucoidan
9072-19-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM